Nanotherapeutics Of Gallic Acid For Cancer Therapy: A Mini Review

Abstract

The low solubility and absorption, around 40–70% of therapeutic compounds in clinical drug development, have bioavailability problems. Research shows that techniques based on nanotechnology can improve the pharmacokinetic characteristics of medications. Gallic acid (GA) is a member of the polyphenolic acid class. This study undertakes a comprehensive analysis of gallic acid (GA) encapsulated within gallic acid nanocarriers for cancer treatment, focusing on the advancements in nanoparticle technology that enhance GA’s pharmacological activities by overcoming its systemic clearance and bioavailability limitations, thereby optimizing its anticancer activity. These approaches allow for better modulation of important cancer-related pathways such as PI3K/Akt and NF-κB, controlled release, and less toxicity. This review focuses on the molecular mechanisms, transport methods, and clinical translation potential of GA-loaded nanocarriers in cancer therapy.